PE20121086A1 - Compuestos de azetidinona y uso medico de los mismos - Google Patents

Compuestos de azetidinona y uso medico de los mismos

Info

Publication number
PE20121086A1
PE20121086A1 PE2012000185A PE2012000185A PE20121086A1 PE 20121086 A1 PE20121086 A1 PE 20121086A1 PE 2012000185 A PE2012000185 A PE 2012000185A PE 2012000185 A PE2012000185 A PE 2012000185A PE 20121086 A1 PE20121086 A1 PE 20121086A1
Authority
PE
Peru
Prior art keywords
alkyl
fluorophenyl
halogen
cyane
trifluoromethyl
Prior art date
Application number
PE2012000185A
Other languages
English (en)
Inventor
Hua Bia
Xuyang Zhao
Xiaojie Xu
Xiaoyu Liu
Ying Chen
Xiaohe Zheng
Maojian Gu
Qifeng Zhu
Yong Zhang
Hairong Luo
Yuncai Zhang
Original Assignee
Zhejiang Hisun Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharm Co Ltd filed Critical Zhejiang Hisun Pharm Co Ltd
Publication of PE20121086A1 publication Critical patent/PE20121086A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/26Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, R1 ES 1-3 SUSTITUYENTES DE H, HALOGENO, TRIFLUOROMETILO, CIANO, ALQUILO C1-C6, ENTRE OTROS; R2 ES 1-3 SUSTITUYENTES DE H, HALOGENO, TRIFLUOROMETILO, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R3 ES 1-3 SUSTITUYENTES DE H, HALOGENO, BENCILOXILO, ALCOXILO C1-C6, CIANO, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ALQUENILO C2-C6, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, CICLOALQUILO C3-C6; R6 ES H, -COR7; R7 ES ALQUILO C1-C10, FENILO SUSTITUIDO O NO CON HALOGENO, TRIFLUOROMETILO, CIANO, ENTRE OTROS; m ES 0-3; n ES 1-3. SON COMPUESTOS PREFERIDOS: (3R,4S)-1-(4-FLUOROFENIL)-3-[(Z)-3-(4-FLUOROFENIL)-4-HIDROXI-BUT-2-ENIL]-4-(4-HIDROXIFENIL)AZETIDIN-2-ONA; (4R,4S)-1-(4-FLUOROFENIL)-3-[(E)-3-(4-FLUOROFENIL)-4-HIDROXI-BUT-2-ENIL]-4-(4-FENOXIFENIL)AZETIDIN-2-ONA; ENTRE OTROS. DICHOS COMPUESTOS PUEDEN REDUCIR LOS NIVELES DE COLESTEROL TOTAL Y COLESTEROL DE LIPOPROTEINAS DE BAJA DENSIDAD EN PLASMA
PE2012000185A 2009-08-11 2010-08-09 Compuestos de azetidinona y uso medico de los mismos PE20121086A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101628888A CN101993403B (zh) 2009-08-11 2009-08-11 氮杂环丁酮类化合物及医药应用

Publications (1)

Publication Number Publication Date
PE20121086A1 true PE20121086A1 (es) 2012-08-17

Family

ID=43585888

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000185A PE20121086A1 (es) 2009-08-11 2010-08-09 Compuestos de azetidinona y uso medico de los mismos

Country Status (18)

Country Link
US (1) US8623855B2 (es)
EP (1) EP2465847B1 (es)
JP (1) JP5706896B2 (es)
KR (1) KR101394993B1 (es)
CN (2) CN101993403B (es)
CA (1) CA2770793C (es)
CL (1) CL2012000351A1 (es)
EA (1) EA021484B1 (es)
IL (1) IL218045A (es)
IN (1) IN2012DN01132A (es)
MX (1) MX2012001829A (es)
MY (1) MY157237A (es)
NZ (1) NZ598050A (es)
PE (1) PE20121086A1 (es)
SG (1) SG178313A1 (es)
UA (1) UA105053C2 (es)
WO (1) WO2011017907A1 (es)
ZA (1) ZA201201676B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
HK1210143A1 (en) * 2012-09-05 2016-04-15 浙江海正药业股份有限公司 Crystal forms of azetidinone compounds and preparing methods thereof
CN104780918B (zh) * 2013-03-01 2017-03-08 浙江海正药业股份有限公司 用于预防和/或治疗丙型肝炎的氮杂环丁酮化合物及其组合物
CN105294426B (zh) * 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
WO2019101150A1 (zh) * 2017-11-23 2019-05-31 浙江海正药业股份有限公司 一种海泽麦布片剂及其制备方法
WO2019101151A1 (zh) * 2017-11-23 2019-05-31 浙江海正药业股份有限公司 一种海泽麦布和HMG-CoA还原酶抑制剂的药物组合物
WO2022262768A1 (zh) * 2021-06-17 2022-12-22 浙江海正药业股份有限公司 海泽麦布中间体及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2525125B2 (ja) 1991-07-23 1996-08-14 シェリング・コーポレーション 血清コレステロ―ル低下薬として有用な置換β−ラクタム化合物およびそれらの製法
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
CA2191455A1 (en) 1994-06-20 1995-12-28 Wayne Vaccaro Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
EP0877750B1 (en) 1995-10-31 2002-06-19 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ES2287826T3 (es) 2000-12-20 2007-12-16 Schering Corp 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos.
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
EP1345895B1 (de) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
MXPA03005019A (es) 2000-12-21 2003-09-25 Avantis Pharma Deutschland Gmb Derivados de difenilazetidinonas, metodo para su produccion farmacos que contienen estos compuestos y su uso.
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
DE10227507A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227508A1 (de) 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
US7696177B2 (en) * 2005-06-15 2010-04-13 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
CN101134739A (zh) * 2006-09-01 2008-03-05 长春吉大天元化学技术股份有限公司 新的β-内酰胺类化合物及其制备方法及其药物用途
WO2008057948A2 (en) * 2006-11-01 2008-05-15 Ironwood Pharmaceuticals, Inc. Processes for production of diphenylylazetidin-2-ones and related compounds
US20080280836A1 (en) * 2007-05-08 2008-11-13 Morriello Gregori J Anti-hypercholesterolemic biaryl azetidinone compounds
CN101423511A (zh) * 2007-11-05 2009-05-06 中山奕安泰医药科技有限公司 依泽替米贝中间体及依泽替米贝的合成方法
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用

Also Published As

Publication number Publication date
MY157237A (en) 2016-05-13
US20120208994A1 (en) 2012-08-16
EP2465847A4 (en) 2013-04-17
WO2011017907A1 (zh) 2011-02-17
IL218045A (en) 2017-05-29
KR101394993B1 (ko) 2014-05-15
AU2010282097A1 (en) 2012-04-05
JP5706896B2 (ja) 2015-04-22
EA201270248A1 (ru) 2012-07-30
CA2770793C (en) 2017-06-13
ZA201201676B (en) 2012-11-28
CN101993403B (zh) 2012-07-11
CA2770793A1 (en) 2011-02-17
US8623855B2 (en) 2014-01-07
EA021484B1 (ru) 2015-06-30
IL218045A0 (en) 2012-04-30
EP2465847A1 (en) 2012-06-20
CL2012000351A1 (es) 2012-08-10
SG178313A1 (en) 2012-03-29
MX2012001829A (es) 2012-07-23
UA105053C2 (uk) 2014-04-10
CN101993403A (zh) 2011-03-30
CN102448932B (zh) 2014-08-13
NZ598050A (en) 2013-03-28
IN2012DN01132A (es) 2015-04-10
CN102448932A (zh) 2012-05-09
JP2013501734A (ja) 2013-01-17
KR20120047969A (ko) 2012-05-14
EP2465847B1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
PE20121086A1 (es) Compuestos de azetidinona y uso medico de los mismos
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20090772A1 (es) Derivados de bencimidazol
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
PE20090549A1 (es) Derivados de imidazolidinona con actividad sobre lxr-alfa y lxr-beta
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
ATE504565T1 (de) Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
CY1118007T1 (el) Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
ATE439349T1 (de) Cyclische anilinopyridinotriazine als gsk-3- inhibitoren
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20140236A1 (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
PE20110805A1 (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
PE20131377A1 (es) Triazina-oxadiazoles
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
PE20140934A1 (es) Derivados de pirazol
EA201390717A1 (ru) 3-(аминоарил)пиридиновые соединения
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb

Legal Events

Date Code Title Description
FG Grant, registration